What are the differential diagnoses and initial work‑up for a mild hypercalcemia with serum calcium 10.5 mg/dL (normal 8.6‑10.2)?

Differential Diagnosis and Initial Work-Up for Mild Hypercalcemia (10.5 mg/dL)

For a serum calcium of 10.5 mg/dL (mildly elevated above the normal range of 8.6–10.2 mg/dL), the most critical first step is to measure intact parathyroid hormone (PTH) to distinguish between PTH-dependent causes (primarily primary hyperparathyroidism) and PTH-independent causes (malignancy, granulomatous disease, medications, or other etiologies). 1, 2

---

Initial Laboratory Assessment

The diagnostic algorithm begins with a focused laboratory panel that determines the underlying mechanism:

• Measure intact PTH immediately – this single test distinguishes the two major categories of hypercalcemia and guides all subsequent evaluation. 1, 2, 3
• Calculate corrected calcium using the formula: Corrected calcium (mg/dL) = Total calcium + 0.8 × [4.0 – Serum albumin (g/dL)]. This accounts for protein binding and confirms true hypercalcemia. 1, 4
• Check ionized calcium if albumin is abnormal, acid-base disturbances are present, or the corrected calcium calculation seems discordant with clinical presentation, because ionized calcium represents the physiologically active fraction. 1, 4
• Obtain serum phosphorus, magnesium, creatinine, and BUN to assess renal function and identify patterns that suggest specific etiologies (e.g., low phosphorus in hyperparathyroidism, elevated creatinine in malignancy-associated hypercalcemia). 1, 3

---

Interpretation of PTH Results

PTH Elevated or Inappropriately Normal (≥20 pg/mL)

This pattern indicates PTH-dependent hypercalcemia, most commonly primary hyperparathyroidism (PHPT), which accounts for the majority of ambulatory hypercalcemia cases. 2, 3, 5

• Primary hyperparathyroidism typically presents with mild, chronic hypercalcemia (calcium <12 mg/dL), subtle or absent symptoms, and a duration >6 months. 3, 5
• Associated findings include low serum phosphorus, hyperchloremic metabolic acidosis, history of kidney stones, and absence of anemia. 3, 5
• Risk factors favoring PHPT include postmenopausal state, family history of hyperparathyroidism or multiple endocrine neoplasia (MEN), history of head/neck radiation, thiazide diuretic use, or renal calculi. 5
• Parathyroidectomy is considered for patients <50 years, calcium >1 mg/dL above upper normal limit, evidence of skeletal disease (osteoporosis, fractures), or renal involvement (stones, reduced GFR). 2
• Observation with monitoring is appropriate for patients >50 years with calcium <1 mg/dL above upper limit and no end-organ damage. 2

PTH Suppressed (<20 pg/mL)

Suppressed PTH indicates PTH-independent hypercalcemia, requiring further evaluation for malignancy, granulomatous disease, medications, or endocrinopathies. 2, 3

Malignancy Work-Up (Most Common PTH-Independent Cause)

• Malignancy accounts for up to 65% of hospitalized hypercalcemic patients and typically presents with rapid onset, higher calcium levels (often >12 mg/dL), severe symptoms, and marked anemia. 3, 5
• Measure PTH-related protein (PTHrP) – elevated in the majority of malignancy-associated hypercalcemia cases, particularly solid tumors (lung, breast, renal cell carcinoma). 1, 2
• Obtain serum protein electrophoresis, immunofixation, and free light chains to screen for multiple myeloma if monoclonal protein is suspected. 1
• Order cross-sectional imaging (CT chest/abdomen/pelvis) and bone scan when solid-tumor bone metastases are suspected based on clinical context. 1

Granulomatous Disease and Vitamin D Disorders

• Measure both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D together – granulomatous diseases (sarcoidosis, tuberculosis) and lymphomas cause elevated 1,25-(OH)₂ vitamin D due to extrarenal 1α-hydroxylase activity in macrophages. 6, 1, 2
• In sarcoidosis, hypercalcemia occurs in approximately 6% of patients, with 84% having low 25-OH vitamin D but 11% having elevated 1,25-(OH)₂ vitamin D. 6
• Vitamin D intoxication presents with elevated 25-OH vitamin D (typically >150 ng/mL) and suppressed PTH. 1, 2

Medication and Supplement Review

• Thiazide diuretics reduce urinary calcium excretion and can unmask or worsen hyperparathyroidism. 2, 5
• Excessive calcium supplementation (>500 mg/day), vitamin D (>400 IU/day), or vitamin A can cause hypercalcemia. 1, 2
• Lithium increases the PTH set-point and can cause hypercalcemia with elevated or normal PTH. 2
• Calcitriol and vitamin D analogues (paricalcitol) cause hypercalcemia in 22.6–43.3% of patients in clinical trials. 1
• Denosumab discontinuation, immune checkpoint inhibitors, and SGLT2 inhibitors are rare causes (<1%) but should be considered in the appropriate clinical context. 2

Other Etiologies

• Immobilization causes increased bone resorption, elevated urinary calcium, low 1,25-(OH)₂ vitamin D, and suppressed PTH; it is more common in young patients with acute paralysis or prolonged bed rest. 7
• Hyperthyroidism increases bone turnover and can cause mild hypercalcemia with suppressed PTH. 2
• Familial hypocalciuric hypercalcemia (FHH) presents with lifelong mild hypercalcemia, low urinary calcium excretion (<100 mg/24 hours or calcium/creatinine clearance ratio <0.01), and inappropriately normal PTH; it requires no treatment. 2

---

Clinical Context and Symptom Assessment

• Mild hypercalcemia (calcium <12 mg/dL or ionized calcium 5.6–8.0 mg/dL) is usually asymptomatic but may cause fatigue, constipation, polyuria, or polydipsia in approximately 20% of patients. 1, 2
• Severe hypercalcemia (calcium ≥14 mg/dL or ionized calcium ≥10 mg/dL) or rapid onset causes nausea, vomiting, dehydration, confusion, somnolence, coma, and shortened QT interval on ECG. 1, 2
• Duration of hypercalcemia helps distinguish chronic PHPT (>6 months, stable) from acute malignancy-associated hypercalcemia (days to weeks, progressive). 3, 5

---

Common Pitfalls to Avoid

• Do not rely on corrected calcium alone when albumin is abnormal – measure ionized calcium directly to avoid misclassification, as correction formulas have limitations outside normal albumin ranges. 1, 4
• Do not assume asymptomatic hypercalcemia is benign – even mild elevations warrant full evaluation, as 90% of cases are due to PHPT or malignancy. 2, 3
• Do not measure PTH in isolation – always interpret PTH in the context of serum calcium, phosphorus, and renal function, as PTH loses predictive value when calcium is elevated. 1, 5
• Do not overlook medication history – thiazides, lithium, calcium/vitamin D supplements, and calcitriol are common iatrogenic causes that are easily reversible. 1, 2
• Do not delay PTHrP measurement when PTH is suppressed – this is the most efficient next step to identify malignancy-associated hypercalcemia. 1, 2

---

Summary Algorithm

1. Confirm true hypercalcemia by calculating corrected calcium or measuring ionized calcium. 1, 4
2. Measure intact PTH to distinguish PTH-dependent from PTH-independent causes. 1, 2, 3
3. If PTH elevated/normal: Evaluate for primary hyperparathyroidism (imaging, bone density, renal function) and consider parathyroidectomy vs. observation based on age and end-organ involvement. 2, 5
4. If PTH suppressed: Measure PTHrP, 25-OH and 1,25-(OH)₂ vitamin D, review medications, and pursue malignancy work-up (SPEP, imaging) as clinically indicated. 1, 2
5. Assess symptom severity and treat accordingly – mild asymptomatic hypercalcemia requires no acute intervention, while severe symptomatic hypercalcemia requires immediate hydration and bisphosphonates. 1, 2